Company profile: Mersana Therapeutics
1.1 - Company Overview
Company description
- Provider of biodegradable polymer and ADC platforms, including Fleximer; Dolasynthen to generate site-specific, homogeneous ADCs with proprietary payloads and target-optimized drug-to-antibody ratios; and Immunosynthen to create STING agonist ADCs that locally activate STING signaling. Pipeline includes XMT-1660 (B7-H4) and XMT-2056 targeting a novel HER2 epitope.
Products and services
- Immunosynthen: Architects ADCs with a novel immunomodulatory STING agonist to locally activate STING signaling in tumor-resident immune cells and antigen-expressing cells
- Dolasynthen: Creates site-specific, homogeneous ADCs with a proprietary payload and tunable drug-to-antibody ratio matched to specific targets to maximize therapeutic index
- XMT-1660: A B7-H4-directed Dolasynthen ADC with a target-optimized drug-to-antibody ratio and proprietary cytotoxic payload, engineered to treat breast, endometrial, and ovarian tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mersana Therapeutics
Telesta Therapeutics
HQ: Canada
Website
- Description: Provider of transformative human therapeutics, focused on licensing, acquisition, development, manufacturing and commercialization of novel medicines addressing major unmet medical needs, particularly in oncology; anchor product MCNA has completed a Phase III pivotal study.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Telesta Therapeutics company profile →
Baliopharm
HQ: Germany
Website
- Description: Provider of novel therapeutics developing monoclonal and bispecific antibodies for autoimmune diseases, chronic liver diseases such as NASH, B-cell malignancies, and cancer. Products include Atrosab and Atrosimab, TNF-R1 targeting antibodies for liver and immune-mediated inflammatory diseases, and Novotarg, a CD20/CD95-targeting bispecific for autoimmune diseases and B-cell malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Baliopharm company profile →
Vaxart
HQ: United States
Website
- Description: Provider of oral vaccine pills and vaccine technology for infectious diseases, including COVID-19 (Phase II, room-temperature stable for easier global distribution), norovirus (Phase 1), influenza (Phase 1 completed for H1N1 and influenza B), RSV (targeting vulnerable populations), and an HPV therapeutic vaccine for types 16 and 18, built on the VAAST™ platform using Ad5 to deliver antigens and adjuvants to mucosal cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxart company profile →
Cangene
HQ: United States
Website
- Description: Provider of immune therapeutics through fully integrated development and manufacturing, with a solid track record of developing and commercializing plasma-derived products that address multiple therapeutic areas; first drug WinRho SDF has been commercially available since 1980.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cangene company profile →
Vaccinogen
HQ: United States
Website
- Description: Provider of vaccines and other immunotherapeutic products for cancers and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaccinogen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mersana Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mersana Therapeutics
2.2 - Growth funds investing in similar companies to Mersana Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mersana Therapeutics
4.2 - Public trading comparable groups for Mersana Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →